Thursday, May 18, 2017 9:41:56 AM
Poster to be Presented at 2017 ASCO Annual Meeting
ROCKVILLE, Md., May 18, 2017 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported the availability of an abstract titled "Phase II Clinical and Molecular Trial of Oral ENMD-2076 in Clear Cell Ovarian Cancer (CCOC)" that was published on May 17, 2017 and is the subject of a poster to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2-6, 2017 in Chicago, Illinois. The abstract is available at: http://abstracts.asco.org.
Alex Zukiwski, M.D., CASI's Chief Medical Officer, commented, "The abstract analyzes the data from an investigator-initiated study of ENMD-2076 in pretreated patients with recurrent CCOC conducted by the Princess Margaret Phase 2 Consortium. The trial completed enrollment of 40 patients (37 evaluable) with biomarker analysis still ongoing. The primary endpoints of the study were progression free survival rate (PFS) at 6 months and objective response rate. Exploratory objectives incorporated evaluation of correlative biomarkers on patient outcomes, including the evaluation of ARID1A status which is a known negative prognostic factor in CCOC. The estimated six-month PFS rate was 20% for the evaluable patients, 31% for patients with ARID1A loss, and 12% for patients with ARID1A positive. Median PFS was 3.7 months (m) (95%CI: 3.4-4.4m), in ARID1A loss (19 pts) was 4.1m (95%CI: 3.5-10.3m) vs 3.6m (95%CI: 1.7-3.9m) in ARID1A positive (17 pts) (p=0.024). The loss of ARID1A on archival tissue seems to be associated with better PFS on ENMD-2076. Two patients achieved a partial response (1 unconfirmed) as per RECIST v1.1 criteria."
Dr. Zukiwski continued, "CCOC is a rare type of ovarian cancer which is difficult to treat and is shown to be relatively non responsive to standard chemotherapy agents. The identification of what appears to be an improved PFS in the patient group with ARID1A loss is encouraging and needs to be further assessed as this potential biomarker could allow for selection of patients who may potentially benefit from ENMD-2076. Evaluation of the clinical data and the correlative biomarker program continues and will help determine the development path in CCOC and potentially for the other tumor types for which ARID1A loss or mutation has been identified."
Recent CASI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/12/2024 11:30:34 AM
- CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE • PR Newswire (US) • 09/04/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/04/2024 04:15:05 AM
- Form F-3/A - Registration statement by foreign private issuers: [Amend] • Edgar (US Regulatory) • 08/29/2024 12:00:51 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/16/2024 09:01:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 12:30:21 PM
- CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 08/16/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 10:18:15 AM
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 07/19/2024 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/19/2024 10:07:25 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/08/2024 11:48:21 AM
- CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP • PR Newswire (US) • 07/08/2024 11:30:00 AM
- CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company • PR Newswire (US) • 06/26/2024 08:15:00 PM
- CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He • PR Newswire (US) • 06/26/2024 08:10:00 PM
- CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) • PR Newswire (US) • 05/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 10:50:28 AM
- CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 05/14/2024 12:00:00 PM
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 04/08/2024 09:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 03/28/2024 11:00:00 AM
- CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China • PR Newswire (US) • 03/05/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA • PR Newswire (US) • 02/16/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 11/14/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA • PR Newswire (US) • 11/08/2023 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM